



1636

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to: Mail
Stop DD, Commissioner for Patents, PO Box 1450
Alexandria, VA 22313 on May 21, 2003.

David Saliwanchik
David R. Saliwanchik, Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1636
Patent Application
Docket No. SPO-112
Serial No. 09/762,842

#13

RECEIVED

MAY 28 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Examiner : Celine X Qian, Ph.D.
Art Unit : 1636
Applicants : Murasugi Akira, Asami Yukio, Kido Isao and Kumai Hideshi
Serial No. : 09/762,842
Filed : February 12, 2001
Conf. No. : 1096
For : High Level Secretary Expression System of Intact MK Family Protein

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRS/la

Enclosures: Form PTO/SB/08; and
Copies of references cited therein.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/762,842
Filing Date	February 12, 2001
First Named Inventor	Murasugi Akira
Group Art Unit	1636
Examiner Name	Celine X Qian, Ph.D.
Attorney Docket Number	SPO-112

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	MILNER, PETER G., SHAH, DULARI, VEILE, ROSALIE, DONIS-KELLER, HELEN and KUMAR, VIJAYA (1992) "Cloning, Nucleotide Sequence, and Chromosome Localization of the Human Pleiotrophin Gene" <i>Biochemistry</i> 31(48):12023-12028.	
	R2	Database Geneseq Accession No. AAT12736, 1994.	
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

RECEIVED

MAY 28 2003

TECH CENTER 1600/2900

Examiner
Signature

Date
Considered

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

